Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29227517 | 0.80 | DDR1 (0.46) | VNN1KCNH2LOXL2LOXSMARCA2 | |
| SCHEMBL16056650 | 0.80 | PTPN1 (0.50) | VNN1KCNH2LOXL2LOXSMARCA2 | |
| SCHEMBL30016275 | 0.80 | PTPN1 (0.50) | VNN1KCNH2LOXL2LOXSMARCA2 | |
| SCHEMBL28647663 | 0.79 | JMJD6 (0.43) | VNN1KCNH2LOXL2LOXSMARCA2 | |
| SCHEMBL25334034 | 0.77 | PLOD2 (0.61) | VNN1KCNH2LOXL2LOXSMARCA2 | |
| SCHEMBL29227518 | 0.77 | VNN1 (0.44) | VNN1KCNH2LOXL2LOXSMARCA2 | |
| SCHEMBL3587253 | 0.77 | TRPV4 (0.41) | VNN1KCNH2 | |
| SCHEMBL28019417 | 0.77 | VNN1 (0.58) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL2686060 | 0.76 | KCNH2 (0.38) | KCNH2SMARCA2SMARCA4 | |
| SCHEMBL4656010 | 0.76 | PREP (0.42) | KCNH2LOXL2LOXSMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861597-B1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2017-09-06 | — | — | EP | disclosed |
| US-9434734-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2016-09-06 | — | — | US | disclosed |
| US-20150105381-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105381-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRIN1, GRM2 | VNN1 4558/4885KCNH2 1156/4885LOXL2 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.